Articles
8 June 2009
Vol. 2 No. 7: New Insights in Hematology, Venice (Italy), May 14-17, 2006
https://doi.org/10.4081/hmr.v2i7.406

New approaches to front-line therapy in multiple myeloma patients aged over 60 years

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
186
Views
184
Downloads

Authors

JF San-Miguel
support@pagepress.org
MV Mateos
High dose therapy followed by autologous stem cell support (ASCT) represents the standard of care for younger myeloma patients. However, half of MM patients are >70 years at diagnosis and other have comorbidetes which preclude ASCT. For more than 30 years Melphalan-Prednisone (MP) has been the standard treatment for elderly MM patients, although the response rate (RR) is only 40-50% and complete responses (CR) are rare. Median duration of response to MP is 1.5 years and median O.S is 2-3 years.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



New approaches to front-line therapy in multiple myeloma patients aged over 60 years. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.406